# Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

> **NCT06561308** · PHASE2 · RECRUITING · sponsor: **Women's Hospital School Of Medicine Zhejiang University** · enrollment: 39 (estimated)

## Conditions studied

- Endometrioid Endometrial Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT06561308
- **Lead sponsor:** Women's Hospital School Of Medicine Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2031-12-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-12-01

## Collaborators

- Xiangya Hospital of Central South University
- Tongji Hospital
- Qilu Hospital of Shandong University
- Anhui Provincial Cancer Hospital
- Sichuan Cancer Hospital and Research Institute
- Henan Provincial People's Hospital
- Hunan Cancer Hospital
- Zhejiang Cancer Hospital
- First Affiliated Hospital of Wenzhou Medical University
- Ningbo No. 1 Hospital
- The First Affiliated Hospital of Zhengzhou University

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561308, "Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06561308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*